Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
about
Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.Phylogenetic relationships of the HA and NA genes between vaccine and seasonal influenza A(H3N2) strains in KoreaNeuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time.Signaling by Antibodies: Recent Progress.A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.The Optimisation of Pseudotyped Viruses for the Characterisation of Immune Responses to Equine Influenza Virus.Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.Ultrasensitive Fluorogenic Reagents for Neuraminidase Titration.Induction of IL21 in Peripheral T Follicular Helper Cells Is an Indicator of Influenza Vaccine Response in a Previously Vaccinated HIV-Infected Pediatric Cohort.Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge ModelComparison of the Efficacy of N9 Neuraminidase-specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.Implications of segment mismatch for influenza A virus evolution.Antibodies directed towards neuraminidase N1 control disease in a mouse model of influenza.Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines.Genomic Circuitry Underlying Immunological Response to Pediatric Acute Respiratory Infection.The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines.Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectivenessThe Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza VaccinePolyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus InfectionsAS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralizationImmunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and MiceVaxArray potency assay for rapid assessment of "pandemic" influenza vaccinesThe manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development processComparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses
P2860
Q30400179-116EE368-D135-4B16-B94B-6C4FA8683B9DQ36296560-76D9EC69-3FD7-4EC2-BDE7-37A52A33377EQ36408162-6AA19EB5-B3EB-46E2-BCD7-7D24C13AA79EQ37591325-2F543ED5-EB8F-48CE-96DB-031FF3791407Q39264890-938B1A0A-60CB-4B8B-BAE2-4E10FB13D48BQ39397313-BB54204E-625E-44B1-B83E-7F0346B40CA5Q39534931-4D710B5F-8B3F-418F-B24F-10F901298924Q40056879-4B586951-2FB3-4AE1-999D-EC3D32D5B63CQ40075978-D0D3DD91-D830-4244-AD5C-B0206A9329F6Q40248004-AAD41103-823F-41D6-B325-00D6C7ED255AQ40334782-87516095-1239-4D50-8DDA-610AE930271FQ40335210-4C8B52A4-7A26-4460-90FD-ECF1DB3E3AFCQ40355338-1FB38AD0-34FD-4795-A2D5-96BA74079D42Q41676246-AB142C10-81DF-418C-8281-F78F0EE24F87Q45324380-AFFDA064-FF62-49E2-BABC-B54D3DC62171Q47290634-4F4A4B29-E85E-4337-B303-FAFDA145EBEDQ47426452-0EE4D997-CE87-4B6F-A1A0-BC188B9CC026Q47549564-0F95FFCF-67BF-423C-BF7A-703A1217B76BQ47551663-8BCFDFE2-A5EC-416A-8C31-20020767B397Q47556008-4D005161-4125-41FE-A080-D3AA8BE5E736Q47564262-97661EF9-B907-41EB-A275-8338EA61BE0EQ47576940-9F86F175-53DD-4CE3-B886-30437CC3FC76Q49829189-9D0A0FAB-0126-40A6-BF89-C8CE782BBAFDQ52602393-6EB12024-F2B8-49E6-A529-92F5BF22B50CQ52609074-03102F7F-EA06-472B-8FD7-8BDE19B48469Q52627557-1C5C9F0A-F2F9-41FE-9920-DBC327F99E1EQ52671135-B7E4CD6C-7C67-43F7-9BD6-40FD5A202B01Q55447639-8D1719B2-602E-45B9-AB74-318C1A8CB9A4Q57094018-B2952A32-4B1D-4605-8111-3AE5292EDB05Q57094348-6FF22403-4849-4B11-8B33-A62911637191Q57167166-8D7BE145-5CB7-41D7-BB11-E9946FD0B42DQ57299518-99FCA396-DBCD-4A2B-A921-C68C55507192Q57469949-6E479296-9198-41B8-AB42-FA3CEB75BEC0Q57481875-4026C9B2-CA8E-4AAA-827E-763D9F465F11Q58696366-CB8B1027-967A-4279-871B-01E20F59D471Q58706119-46330582-EE15-45A1-B614-3033C422DA8E
P2860
Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@en
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@nl
type
label
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@en
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@nl
prefLabel
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@en
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of Antihemagglutini ...... Healthy Human Challenge Model.
@en
P2093
Alison Han
John H Powers
Kyle Risos
Lindsay Czajkowski
Pamela A Shaw
Rani Athota
Richard T Davey
Sarah Fargis
Susan Reed
Tyler Bristol
P2860
P304
P356
10.1128/MBIO.00417-16
P577
2016-04-19T00:00:00Z